Metabolomic signatures in liquid biopsy are associated with overall survival in metastatic melanoma patients treated with immune checkpoint inhibitor therapy.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs), such as anti-Cytotoxic T-Lymphocyte Antigen 4(CTLA-4) and anti-Programmed cell death protein 1 (PD-1) agents, have improved the prognosis of patients with metastatic melanoma. However, a proportion of patients develop resistance to these treatments, leading to a poor prognosis. Therefore, identifying potential non invasive and easy to measure biomarkers is crucial for guiding treatment strategies in patients with metastatic melanoma.

Methods

A retrospective single-center study was conducted involving patients with metastatic stage IV melanoma who received first-line treatment with anti-CTL4 and/or anti-PD-1 agents. The patients were categorized into two groups on the basis of their 1-year overall survival (OS): those with good

SUBMITTER: Costantini S 

PROVIDER: S-EPMC11983745 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature